hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3–Erk1/2 Signaling Pathway
Anticancer Research · 2024
DOI: 10.21873/anticanres.17097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Sehyeon Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Companion Animal Industry, College of Health Science, Honam University, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: Apoptosis, Cell Proliferation, Disease Progression, MAP Kinase Signaling System.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Companion Animal Industry, College of Health Science, Honam University, Gwangju, Republic of Korea.
- School of Life Science, BK21 FOUR KNU Creative Bioresearch Group, Kyungpook National University, Daegu, Republic of Korea.
- Core Protein Resources Center, DGIST, Daegu, Republic of Korea.
- Division of Biomedical Technology, DGIST, Daegu, Republic of Korea.
- College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea.
- J INTS BIO Inc., Seoul, Republic of Korea.
Zitieren
APA
Han, S., Jang, S., Lee, S. W., Kim, H. Y., Kim, W., Kim, H. G., Park, J. K., Han, J. E., Ryoo, Z. Y., Seah, E., Kim, C., Lee, J., Park, S., & Choi, S. K. (2024). hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3–Erk1/2 Signaling Pathway. Anticancer Research. https://doi.org/10.21873/anticanres.17097
Vancouver
Han S, Jang S, Lee SW, Kim HY, Kim W, Kim HG, et al. hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3–Erk1/2 Signaling Pathway. Anticancer Research. 2024. doi:10.21873/anticanres.17097
BibTeX
@article{Han2024,
author = {Han, Sehyeon and Jang, Soyoung and Lee, Seoung-Woo and Kim, Hee-Yeon and Kim, Wansoo and Kim, Hyeon-Gyeom and Park, Jin-Kyu and Han, Jee Eun and Ryoo, Zae Young and Seah, Ethan and Kim, Choonok and Lee, Jiyeon and Park, Song and Choi, Seong-Kyoon},
title = {hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3–Erk1/2 Signaling Pathway},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17097}
}
EUVIMED